Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: Jefferson Research
Provider: Stock Traders Daily

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomarin Pharmaceutical Inc Updates FY 2012 Revenue Guidance-Conference Call

Monday, 7 Jan 2013 06:30pm EST 

Biomarin Pharmaceutical Inc announced that it expects around $500 million of revenues in fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $497 million for fiscal 2012. 

Related Company News

Company Quote

6.02 +8.03%
24 Oct 2014